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Summary
Objective: Retention rates of five new anti-epileptic medications (AEDs) were com-
pared in order to evaluate their long-term tolerability and efficacy.
Method: We acquired the retention data on levetiracetam (LEV), lamotrigine (LTG),
oxcarbazepine (OXC), topiramate (TPM), and zonisamide (ZNS) from the electronic
database. The data included patient’s age, gender, seizure type, current and previous
medications, dosage, main reasons for discontinuation, and duration of therapy. The
retention rates of these AEDs were evaluated at 4, 12, 24, 52, and 104 weeks.
Results: A total of 828 new AED exposures were obtained (LEV = 196, LTG = 251,
OXC = 97, TPM = 156, ZNS = 128) from patients with partial or generalized epilepsy. At
2 years, retention rate was highest with LTG (74.1%), followed by ZNS (60.2%), OXC
(58.8%), LEV (53.6%), and TPM (44.2%). When these AEDs were discontinued, it was
mainly due to inefficacy (29.5%) and sedating side-effects (20.5%), and commonly
within 6 months into therapy. Several important AED specific side-effects leading to
discontinuation were identified, including behavioral or irritability from LEV, rash
from LTG and OXC, nausea from OXC and ZNS, hyponatremia from OXC, and kidney
stones from TPM and ZNS.
Conclusion: Comparing retention rates of new AEDs can provide useful insight into
their tolerability and efficacy. This study showed highest retention rate with LTG,
which was significantly different from ZNS ( p = 0.0025), LEV ( p < 0.0001), OXC
( p = 0.0024), and TPM ( p < 0.0001). Beside ineffectiveness, other leading causes
of discontinuation were adverse behavioral effects with LEV, rash with LTG and OXC,
and sedation for TPM and ZNS.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.* Corresponding author at: Department of Neurology, 500 West
Thomas Road Suite 300, Phoenix, AZ 85013, USA.
Tel.: +1 602 406 6271; fax: +1 602 798 0852.
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Epilepsy is one of the most common neurological
disorders affecting up to two percent of the. Published by Elsevier Ltd. All rights reserved.
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ple in the United States alone.1—3 Treatment of
epilepsy often imposes an exposure to various
anti-epileptic medications (AEDs) and requires
long-term commitment and compliance from the
patient.4,5 Excluding the small percentage of people
who underwent successful epilepsy surgery, the vast
majority of patients are maintained through chronic
medical management for appropriate seizure con-
trol.6,7 With the advent of the newer generation of
AEDs starting in the early 1990s, eight new agents
for the treatment of epilepsy have been introduced
in the U.S. market.8—10 Although these new AEDs
provided more treatment selection and underwent
FDA-approvals based on randomized double-blind
studies, it is often unclear as to which AED should
be used for each particular patient.10,11 For most
patients, it is a process of trial and error with
different medications, and at times, their combina-
tions.10,12
Minimizing exposures to ineffective or ill-toler-
ated AEDs to patients would improve perceived
quality-of-life and their productivity.13,14 Thus, in
the process of selecting AEDs, patients’ own pre-
ference and input play an important role. Com-
monly, a particular AED is chosen based on seizure
types, drug-to drug interactions, metabolism, dos-
ing convenience, comorbidities, and side effect
profile.12,13,15—18 Even though older AEDs (pheny-
toin, carbamazepine, valproic acid, phenobarbital,
primidone, and ethosuximide) have an advantage of
lower cost, wide availability, and long-term experi-
ence, new AEDs are frequently preferred by neurol-
ogists and patients.10,12,17,19,20
Recent treatment guidelines by French et al.
provide a useful summary for the treatment of
new onset and refractory epilepsy.8,9,21,22 These
guidelines are based on class I and class II studies
from 1,462 articles, and assess information on effi-
cacy, tolerability, and safety of seven new AEDs.
However, in an actual clinical setting, comparison of
their efficacy or side effects (SE) alone does not
adequately address the main question–—will a
patient stay on a drug through the years?
We sought to comprehensively evaluate the reten-
tion rates of commonly usednewAEDs in order to gain
information on how they differ in their treatment
duration, efficacy, and SE in a clinical setting.Methods
Data collection and source population
Retention data on commonly used newer AEDs were
obtained retrospectively by searching establishedelectronic medical records in our epilepsy center
and interviewing patients as needed. To identify
patient exposures to new AEDs, over 2000 patient
records were reviewed and analyzed. In order to
evaluate long-term retention and tolerability, only
the patients who either discontinued their newer
AEDs within 2 years or continued them 2 years or
longer were included. Of these patient records, 828
exposures to the following new AEDs were identified
from 479 patients: lamotrigine (LTG), levetiracetam
(LEV), oxcarbazepine (OXC), topiramate (TPM), and
zonisamide (ZNS). Fewer than 20 epilepsy patients
were identified as being treated with the remaining
new AEDs, such as felbamate (FBM), neurontin
(GBP), tiagabine (TGB), or vigabatrin (VGT). Thus,
these AEDs were excluded from our data analysis.
The data collected included patient’s age, gender,
seizure type, current and previous AED use, dosage,
main reason for discontinuation, and duration of
therapy. Both medical paper charts as well as elec-
tronic records were utilized to avoid as much recall
bias as possible and ensure collected data were
credible and accurate.
Data analysis
Duration of AED therapy was calculated in weeks
from the start date of that particular AED. Dosage
of medication was recorded in maximum daily
doses based on what patient is currently taking
or what dosage patient was discontinued on. Con-
tinuation of therapy was defined for patients cur-
rently treated with same AED since the start of
therapy. Discontinuation of therapy was defined
for patients who stopped treatment at any given
time and main reasons for discontinuation were
recorded based on patients’ complaints whether
they were due to side effects, inefficacy, or other
reasons (Table 4). Side effects were grouped into
categories such as behavioral, fatigue, GI, inef-
fective, rash, kidney stone, hyponatremia, word
finding difficulty and others. Once all data was
entered in Excel, SAS version 2.1.40 was utilized
for further analysis. Survival assessment was made
with parametric analysis by Kaplan—Meier method
as well as nonparametric, multivariate analyses
using the Cox regression analysis.23,24 Within the
Cox model, possible explanatory variables poten-
tially modifying the outcome of retention rate
such as gender, age, or number exposure to other
new AEDs were included and examined for their
significance of effect. In SAS, this was performed
through the use of Proc Phreg.25,26 This form of
analysis was also able to account for possible
effects on retention rate via concurrent AED
usage.
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Table 1 Gender differences among different seizure types
Partial onset IGE SGE Total
Female 398 (48.1) 62 (7.5) 45 (5.4) 505 (61.0)
Male 264 (31.9) 37 (4.5) 22 (2.6) 323 (39.0)
Total 662 (80.0) 99 (12.0) 67 (8.0) 828 (100)
Data are presented in patient number (%). IGE: idiopathic generalized epilepsy; SPG: symptomatic generalized epilepsy.Results
Exposure to new AEDs
Table 1 summarizes the characteristics of the AED
exposures. Of the total 828 data points, there was a
slight predominance with female patient exposures
(61%). Further logistic regression modeling of dura-
tion of medication use did not demonstrate gender
as a significant explanatory variable. The mean age
of exposure was 38.5 years (17—89). Partial onset
seizures were more frequently represented in the
data set (80%), as expected from previous epide-
miological studies. Of the total 479 patients, 408
(85.1%) were continuing to take at least one of the
five new AEDs, while 71 (14.9%) were no longer on
any of them. Among them, 48.2% had been exposed
to only one of the study AEDs, with 30.9% exposed to
two and 13.6% to three of them. The smallest
minorities of 4.8% and 2.5% had exposures to four
and to all five study medications, respectively.
AED use and duration
Overall, the largest number of AED exposure history
was collected from LTG, representing 30.3% of the
data, although LEV data followed closely at 23.7%.
TPM and ZNS data were similar in quantity at 18.8%Table 2 Overall retention rates of different anticonvulsan
LEV LTG OXC
Continued 105 (53.6) 186 (74.1) 57 (
Discontinued 91 (46.4) 65 (25.9) 40 (
Data are presented in patient number (% of continuation or disco
oxcarbazepin; TPM: topiramate; ZNS: zonisamide.
Table 3 Short-term and long-term cumulative discontinua
LEV n = 196 LTG n = 251
4 weeks 27 (13.8) 19 (7.6)
12 weeks 47 (24.0) 38 (15.1)
24 weeks 74 (37.8) 54 (21.5)
52 weeks 85 (43.4) 64 (25.5)
104 weeks 91 (46.4) 65 (25.9)
>104 weeks 94 (48.0) 67 (26.7)
Data are presented in patient number (% discontinuation rate). LE
topiramate; ZNS: zonisamide.and 15.5%, respectively, and the least amount of
data was obtained from OXC exposures at 11.7%
(Table 2). This is probably due to the fact that
OXC was almost exclusively used for partial onset
seizures, while others were used for both partial and
generalized onset seizures.
Further stratification of data at different dura-
tion points is shown in Table 3. The cumulative
numbers of discontinued exposures were calculated
at 4, 12, 24, 52, and 104 weeks. After normalizing
the values by the total number of exposure cases for
each AED, the resulting percentages showed the
most rapid rate of change (i.e. discontinuations)
occurring in the first 24 weeks (Fig. 2). LTG demon-
strated the highest retention rate at 4, 12, 24, 52,
and 104 weeks, while the lowest retention was seen
with LEV at 4 and 12 weeks, and with TPM at 24, 52,
and 104 weeks. Although OXC and ZNS percentages
were between those of LTG and TPM, overlap was
evident among these AEDs at different time points.
For example, interval retention rate was higher with
OXC at 12 and 24 weeks compare to ZNS, but lower
rate was seen later at 104 weeks.
Greater than 80% of patients discontinued AEDs
within 24weeks if theywerediscontinued, regardless
of type of AEDs. For ZNS, more patients tended to
discontinue it early (86% of ZNS discontinued group),
but once passed the 24weeksmark,majority of themts at two years
TPM ZNS Total
58.8) 69 (44.2) 77 (60.2) 494 (59.7)
41.2) 87 (55.8) 51 (39.8) 334 (40.3)
ntinuation rate). LEV: levetiracetam; LTG: lamotrigine; OXC:
tion rates of AEDs
OXC n = 97 TPM n = 156 ZNS n = 128
4 (4.12) 11 (7.1) 14 (10.9)
16 (16.5) 37 (23.7) 29 (22.7)
31 (32.0) 68 (43.6) 44 (34.4)
38 (39.2) 86 (55.1) 50 (39.1)
40 (41.2) 87 (55.8) 51 (39.8)
42 (43.3) 88 (56.4) 51 (39.8)
V: levetiracetam; LTG: lamotrigine; OXC: oxcarbazepin; TPM:
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Figure 1 Cox regression survival curve. Retention rates
of LEV, LTG, OXC, TPM, and ZNS were compared over 2
years. LTG data showed the highest retention rate, which
were significantly different from ZNS ( p = 0.0025), LEV
( p < 0.0001), OXC ( p = 0.0024), and TPM ( p < 0.0001).
TPM was discontinued at the highest rate, significantly
different from OXC ( p = 0.0271) and ZNS ( p = 0.0126)
although not reaching statistical significance with LEV
( p = 0.1342). Retention rates of the other three AEDs
(LEV, OXC, and ZNS) were similar to each other, and no
statistically significant differences were seen (OXC vs. ZNS
at p = 0.9083, OXC vs. LEVat p = 0.3024, and LEV vs. ZNS at
p = 0.2244).LEV: levetiracetam, LTG: lamotrigine, OXC:
oxcarbazepine, TPM: topiramate, ZNS: zonisamide.continued for 2 years, reaching 91.7% continuation
rate after 24 weeks. In contrast, OXC had the lowest
retention rate after 24 weeks (77.3%).
Comparative survival analysis
This pattern for LTG predominance in continuation
of AED use was supported in further survival ana-
lysis. Kaplan—Meier analysis and Cox proportional
regression method (Fig. 1) resulted in similar
curve relationships, demonstrating the included
covariates did not significantly influence results.
Consistent with the prior analyses, LTG dataTable 4 History of prior AEDs use among patients with 2-y
No. of prior study AEDs LEV n (%) LTG n (%)
0 54 (50.0) 101 (57.7
1 47 (30.6) 56 (32.0
2 16 (14.8) 12 (6.9)
3 3 (2.8) 5 (2.8)
4 2 (1.8) 1 (0.6)
Total 108 (100) 175 (100)
LEV: levetiracetam; LTG: lamotrigine; OXC: oxcarbazepin; TPM: toshowed the highest retention rate, which were
significantly different from ZNS ( p = 0.0025), LEV
( p < 0.0001), OXC ( p = 0.0024), and TPM ( p <
0.0001). TPM was discontinued at the highest rate,
significantly different from OXC ( p = 0.0271) and
ZNS ( p = 0.0126) although not reaching statistical
significance with LEV ( p = 0.1342). Retention rates
of the other three AEDs (LEV, OXC, and ZNS) were
similar to each other, and no statistically signifi-
cant differences were seen (OXC versus ZNS at
p = 0.9083, OXC versus LEV at p = 0.3024, and LEV
versus ZNS at p = 0.2244).
Continued drug use and number of prior
drug trials
In Table 4, the instances of continued medication
use were grouped according to the number of prior
study AED trials. In addition to these study AEDs, the
majority of the patients had tried 1 or 2 older AEDs
in the past. The majority of continued medication
use had no or one prior trial of the other four study
AEDs, the percentages ranging from 71.2% for OXC to
89.7% of retained LTG use. Progressively less con-
tinued medication use was seen with more than one
drug trial history. For those who had already tried
two study AEDs previously, the percentages ranged
from 6.9% for LTG to 15.7% for ZNS. For 3 or 4 drug
trials, much lower percentages were seen, from 0 to
9.6%.
Reasons for AED discontinuation
As shown in Table 5, with the exception of LEV, drug
ineffectiveness was the primary reason for stopping
a particular medication; these percentages ranged
from 23.4% of LEV to the maximum at 45.2% of OXC.
In the case of LEV, behavioral side effects accounted
for 40.4% of discontinued cases. Behavioral side
effects included various symptoms including emo-
tional liability, anger outburst, irritability, insom-
nia, and mood swings. This outnumbered the 23.4%
of ineffective cases in this particular AED, which was
the lowest percentage for any of the five AEDs.ear retention
OXC n (%) TPM n (%) ZNS n (%)
) 20 (38.5) 40 (58.8) 27 (32.5)
) 17 (32.7) 17 (25.0) 35 (42.2)
7 (13.4) 9 (13.2) 13 (15.7)
5 (9.6) 2 (3.0) 3 (3.6)
3 (5.8) 0 (0) 5 (6.0)
52 (100) 68 (100) 83 (100)
piramate; ZNS: zonisamide.
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Table 5 Comparison of the reasons for discontinuation among different anticonvulsants
LEV LTG OXC TPM ZNS Total
Ineffective 22 (23.4) 20 (29.9) 19 (45.2) 27 (30.7) 13 (25.5) 99 (29.1)
Behavioral 38 (40.4) 8 (11.9) 2 (4.8) 5 (5.7) 5 (9.8) 58 (17.1)
WFDa 0 (0.0) 0 (0.0) 0 (0.0) 6 (6.8) 1 (2.0) 7 (2.1)
Sedation 23 (24.5) 8 (11.9) 3 (7.1) 24 (27.3) 12 (23.5) 70 (20.6)
Nausea 2 (2.1) 4 (6.0) 4 (9.5) 1 (1.1) 5 (9.8) 16 (4.7)
Kidney stone 0 (0.0) 0 (0.0) 0 (0.0) 3 (3.4) 3 (5.9) 6 (1.8)
Rash 1 (1.1) 18 (26.9) 6 (14.3) 6 (6.8) 4 (7.8) 35 (10.3)
Hyponatremia 0 (0.0) 0 (0.0) 3 (7.1) 0 (0.0) 0 (0.0) 3 (0.9)
Other 8 (8.5) 9 (13.4) 5 (11.9) 16 (18.2) 8 (15.7) 46 (13.5)
Total 94 (100) 67 (100) 42 (100) 88 (100) 51 (100) 340 (100)
Data are presented in number of cases (% of cause for discontinuation). LEV: levetiracetam, LTG: lamotrigine, OXC: oxcarbazepin,
TPM: topiramate, ZNS: zonisamide.
a Word finding difficulty.
Table 6 Mean dose  S.D. differences between continuing and discontinued groups
LEV LTG OXC TPM ZNS
Continued 1985.3  1042.0 392.5  209.6 1236.3  598.6 232.8  143.0 286.7  176.1
Discontinued 1585.1  777.3 294.8  166.4 1100.0  412.0 220.1  144.4 218.0  110.6
LEV: levetiracetam; LTG: lamotrigine; OXC: oxcarbazepin; TPM: topiramate; ZNS: zonisamide.Sedation or fatigue was also high at 24.5% of the
reasons for discontinuing LEV.
LTG was stopped for concern of rashes in 26.9% of
discontinued cases, the highest among the AEDs; no
reports of Steven-Johnson’s reaction were found
among these cases. Behavioral side effects and
sedation/fatigue each resulted in 11.9% cases of
LTG discontinuation.
Rash concern was also high in the OXC disconti-
nuations, accounting for 14.3% of cases, the second
highest after LTG. OXC also had one unique side
effect of hyponatremia, which accounted for 7.1% of
OXC discontinuation causes. Compared with other
AED, OXC had the lowest percentage of behavioral
(4.8%) or sedative side effects (7.1%).
AED discontinuation due to sedating side effect
was the highest with TPM exposure group, which
accounted for 27.3% of TPM discontinuation causes.
Word-finding difficulty was not an infrequent cause
to stop TPM at 6.8%, which was the highest among
these AEDs. Nephrolithiasis was a minor reason to
discontinue TPM accounted for 3.4% and overall
incidence of 1.9% to all TPM exposure group.
Sedation/fatigue was a common reason to stop
ZNS at 23.5%. ZNS had the highest percentage of
gastrointestinal side effects (9.8%) as a reason to
discontinue AEDs. On the other hand, behavioral
side effect was not frequently reported as a cause
to stop ZNS.
The category of ‘other’ included such varied
complaints as paresthesias, allodynia, or indescrib-
able sensations, and monetary cost of medications.The highest percentage was seen in the TPM popula-
tion at 18.2% (mainly paresthesias), accounting for a
large numbers of TPM cessation cases.
Dosage evaluation
Comparison of mean doses between continuing
group and discontinued group for each AED is shown
in Table 6. For each of the five AEDs, t-test of the
dosages demonstrated significant differences
between the continuing and discontinued groups
for LEV (p = 0.0023), LTG ( p = 0.0006), and ZNS
(p = 0.014). For these AEDs, the mean dosages were
higher in the continuing group than the discontinued
group. The mean doses for TPM and OXC groups did
not show significance ( p = 0.5829 and 0.2024,
respectively). There were no significant differences
in mean dosages between continuing group and
discontinued group due to inefficacy.Discussion
Our goal was to provide neurologists with helpful
information in selecting a long-term treatment
among new AEDs. Many factors influence treatment
selection including seizure type, gender, age, con-
current AEDs and other co-medications.27—29 Suc-
cessful treatment should consist of finding the
balance between obtaining adequate seizure con-
trol and avoiding SE, as well as factoring in patient’s
preference,19,30 which can be assessed by AED
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reasons for medication termination including inef-
fectiveness and intolerability. In other words, reten-
tion rate may provide a useful ‘‘feedback’’ on
treatment plans according to patient’s perspective.
This provides practical and useful information to
optimize the pretrial probability that a particular
AED would be successful for the patient. Therefore,
while evidence based information and wider selec-
tion of AEDs empower neurologists to choose treat-
ments, long-term retention rates could provide
useful insights into overall efficacy and tolerabil-
ity.19,30—33 In addition, retention rate also captures
each individual patient’s preference and allows
patients to decide which side effects are tolerable
for them.
There are several caveats when interpret our
retention related SE data. First of all, we reported
only the severe adverse effects those lead to dis-
continuation of AEDs, and thus, they are quite
different from previously reported SE rates.30,34—
36 For example, less severe side effects such as
headache or mild nausea played small parts in our
study but well-known to be very common in other
trials.30,37—40 In other words, even though common,
patients did not perceive them severe enough to
discontinue their AEDs.
In addition, SE rates quoted in our study are
percentage of why that specific AED was discontin-
ued and do not represent overall incidence. For
instance, while nephrolithiasis accounted for nearly
6% of reason to discontinue ZNS, overall incidence of
nephrolithiasis was less than 2% in all ZNS exposure
group. Furthermore, higher retention rate does not
necessarily indicate better efficacy. Not everyone in
our study was seizure-free and many of them con-
tinued to take their AEDs even when they are not
completely efficacious. In this regard, retention
rate may reflect more of AED tolerability rather
than its efficacy. Thus, one should be very cautious
before drawing a conclusion that LTG or ZNS is more
effective than LEV or TPM based on our study. What
our study shows is that LTG was best tolerated
among the studied AEDs with subjective efficacy
against seizures. Furthermore, the order of these
AEDs used had a significant impact on their retention
rates. Previous studies have shown that the efficacy
of AEDs decreases after the 2nd or 3rd AED had
failed.6,18,27 Therefore, a drug used after 2 or 3
prior drug trials may be less likely to be continued
(due to inefficacy) as compared to one that was tried
at an earlier time point. A potential bias affecting
our reported retention rate results would be if one
of the medications was systematically used first.
Although our database was limited to usage of the
five study medications, the consistent trend acrosseach retainedmedication was that it was most likely
to have been preceded by less than two prior drug
trials (Table 4) with large decreases in retention rate
after two or more AED trials. Therefore, within the
confines of the retrospective data available, there
does not appear to be a bias due to a difference in
prior drug use. This could be more concisely
addressed by a long-term prospective study with
newly treated epilepsy cases that would also
account for all AED use.
It is important to point out that when AEDs were
discontinued, most of patients did within 6 months
regardless of their seizure types or gender (Table 2).
This may indicate that effectiveness and tolerability
should be thoroughly evaluated at around 6 months
after initiating AEDs, and prepare patients for a
likely long-term treatment. This study also shows
that after initial hurdle of 6 months, continuation
rate of all AEDs were notably high and exceeded 90%
especially with LTG and ZNS.
There are previously reported retention rates of
new and old AEDs (often comparing old versus
new).37,41—44 However, due to differences in study
designs, prior metanalysis have drawn limited con-
clusions in the indirect comparison of one medica-
tion versus another.34,45,46 Direct comparison
studies have been restricted in number of AEDs,
typically comparing two or three AEDs simulta-
neously.34,46—49 In one retrospective cohort study
of LTG, TPM, gabapentin, and vigabitrine, investi-
gators determined LTG had the longest time to
discontinuation, TPM the shortest.45 However, final
percentage of patients taking LTG and TPM were
similar, at 60% and 50% respectively. Another study
compared tolerability among five AEDs (TPM, TGB,
VGT, GBP, and LTG), and concluded TPM was the
most common drug to be withdrawn due to SE.50
Another similar retrospective cohort study was per-
formed with GBP, LTG, and TPM.51 The study con-
cluded that TPM and LTG had similar retention rates,
although TPM appeared to be more efficacious but
with more side effects. Although a number of reten-
tion studies have been reported for a single
AED,44,52—57 no comparison studies have included
OXC, ZNS, or LEV. This study was therefore under-
taken to directly compare retention rates in the five
commonly used new AEDs in a single epilepsy clinic,
examining the rate of discontinuation, dosing, and
the reasons for stopping.
We evaluated retention rates both in short-term
at 1, 3, and 6 months as well as long-term at 1 and 2
years for all five AEDs. Overall, LTG had the highest
retention rate in the short- and the long-term in our
study, while TPM had the lowest in the long-term
(Figs. 1 and 2). Beside LTG, there was no significant
difference in the short-term retention rates among
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Figure 2 Cumulative medication discontinuation by
percentages over two years. Discontinued exposures were
calculated at 4, 12, 24, 52, and 104 weeks. The highest
discontinuation rate was seen within 24 weeks for all AEDs
(Greater than 80% of patients discontinued AEDs within 24
weeks). LTG demonstrated the lowest discontinuation
rate (or highest retention rate) at 4, 12, 24, 52, and
104 weeks, while the highest discontinuation rate was
seen with LEV at 4 and 12 weeks, and with TPM at 24, 52,
and 104 weeks.the remaining four AEDs. LTG had the highest con-
tinuation rate after 6 months of therapy, which
distinguished it from the rest with a 2-year-reten-
tion rate of 74.1% (Fig. 2). Even though TPM reten-
tion rate was the lowest among five AEDs at 2 years,
it was very similar to previously reported rates of
45—50%.44,45 Many people complained of sedation
and paresthesia, which combined to be about 45% of
the causes to discontinue TPM. We also found that
significantly more people stopped TPM after 6
months into a therapy than any other AEDs. This
may explain why TPM retention rate was low in our
long-term study compare to pervious short-term
studies.58,59 In addition, we also noted that after
6 months, the most common reason to stop TPM was
paresthesia and the other non-specific sensory
symptoms which might have become increasingly
intolerable for patients over time.
In terms of dosages, most of our patients took
medium-average daily doses, perhaps exception of
ZNS (Table 6). Typical dosage for ZNS was ranges
between 200 and 500 mg in the literature even
though efficacy shown even at 100 mg.38,60—64 It is
possible that lower ZNS dosage might have caused
higher retention rate in our study by artificially
improving tolerability. However, many of our
patients continued for a long period of time without
increasing to higher dosage, which may indicateadequate efficacy at that low dosage. It was also
found that ZNS was utilized for both partial and
generalized onset seizures (68% and 32%, respec-
tively) at a similar daily dose.
Beside the comparison of retention rates, sev-
eral findings were noteworthy in our study. First,
retention rates were lower than some of the pre-
vious studies especially with OXC,65 LEV,52 and
TPM.54 This may due to the fact that our study
population has several different baseline charac-
teristics compare to those reported from clinical
trials, such as seizure type, degree of intractability,
concurrent use of specific AEDs, and the length of
follow-up. In addition, more refractory epilepsy
population in our clinic may also have contributed
to overall low retention rate compare to the other
published studies where less severe epilepsy
patients were treated. In fact, it was not a surprise
to find out that the lack of efficacy was the one of
the commonest reason to stop a particular AED.
Second, retention rates were not significantly
different in patients who were taking AEDs as
monotherapy compare to adjunctive therapy.
Furthermore, the order of which AED was used first
among these AEDs did not make a significant impact
on retention rate. This may again due to refractory
patient population in our clinic and the fact that
these AEDs were commonly used as the third, forth,
or fifth choice. And the third, some of the expected
AED-specific adverse events were identified but at
somewhat different rates than previously reported.
For example, approximately 20% of patients
reported behavioral or irritability after LEV therapy
which was significantly higher than the previously
reported incidence.41,66 In fact, this was the lead-
ing cause of discontinuation for LEV (38%). We did
not review their previous psychiatric history and it
is not clear whether this could have been a con-
tributing factor. However, we typically do not initi-
ate LEV for anyone who has or had significant
psychiatric conditions.
On the other hand, the incidence of rash from LTG
in our study (7%) was lower than the previously
reported rate of 10%. Everyone except one person
in our clinic discontinued LTG once benign rash
developed. Exception was a 63-year-old woman
who was switched from phenytoin for partial onset
seizures. Even though she developed a rash on arms
and chest, she decided to continue LTG against our
advice, since she felt much better cognitively with
LTG. She was briefly treated with oral prednisone
and rash disappeared completely within several
days. Rash was one of the main causes for disconti-
nuing OXC as well (14.3%), but only one person from
LEV group discontinued due to rash. Incidence of
symptomatic kidney stone was also somewhat
Comparative retention rates and long-term tolerability of new antiepileptic drugs 303higher than that of reported for both TPM and ZNS at
1.9% and 2.3%, respectively.
There were several limitations of our study
besides the aforementioned ‘‘caveats.’’ These
include absence of information on concurrent older
AEDs and the detailed information how each med-
ication was selected prior to initiation. Even though
we tried tominimize recall bias asmuch as possible,
accuracy of the information could have been still
compromised since it was mainly based on retro-
spective review. The findings are also based on the
limited population in our epilepsy center, which
may not represent other epilepsy or general neu-
rology clinics. Thus, a prospective multi-center
study is needed to further validate the findings of
this study. This study does not contain efficacy
information and our retention rates should not be
interpreted as efficacy data. For example, one can
continue to take medication despite of its lack of
efficacy for various reasons. These may include
consideration of drug-to-drug interaction, lack of
better choice, financial limitation, fear of switching
medications, and other emotional or social circum-
stances. Thus, although higher retention rate may
indicate better tolerance and efficacy overall,
treatment should be tailored to each individual
patient. It would be also useful to obtain a similar
retention rate comparison on pediatric patients to
see if the retention rates are far different from
adult population.Conclusion
We believe that comparing retention rates of newer
AEDs provides useful and practical information in
choosing AEDs. Our study showed the highest reten-
tion rate at 2 years with LTG and lowest with TPM
( p < 0.001). Beside ineffectiveness, the leading
causes of discontinuation of AEDs were irritability
or other behavioral effects for LEV, rash for LTG and
OXC, as well as sedation for TPM and ZNS. We also
found that once these AEDs were tolerated for 6
months, they were highly likely to be continued for
two years or longer.References
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